It is the intent of Howard University to establish an ACTU at the institution for the purpose of conducting AIDS clinical trials with an enrollment focus on African American and Hispanic/Latina populations in the Washington, D.C. metropolitan area. This establishment will extend the efforts which are already underway at the Clinical Trials Unit of the University, which were developed under the Minority Infrastructure Initiative project funded by NIAID. Under this award, the Howard ACTU will recruit a minimum of 75 patients per year to participate in ACTG research studies for the duration of the grant. The initial protocol studies that will be submitted for approval include ACTG 164, ACTG 177 and ACTG 186. In addition, the ACTU will explore the feasibility of undertaking several special research studies involving (a) low dose alpha interferon; (b) an innovative protocol; and (c) a select protocol study underway at other ACTUs. A rationale for considering these areas for special studies is discussed in the Research Plan of the application. In addition, award of the grant will enable the Howard ACTU to increase the involvement in the 4 ACTU protocol studies that are being conducted under the auspices of the Howard University HIV clinic and provide training opportunities for practicing physicians and other health professionals in the management of HIV patients. Through participation as an ACTG member, it is anticipated that the Howard ACTU will be able to make significant contributions toward increasing the number of minority investigators involved in AIDS clinical research, and address the underrepresentation of minority groups in AIDS clinical trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (49))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Howard University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Kiezun, Adam; Garimella, Kiran; Do, Ron et al. (2012) Exome sequencing and the genetic basis of complex traits. Nat Genet 44:623-30
McLaren, Paul J; Ripke, Stephan; Pelak, Kimberly et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 21:4334-47
Pasaniuc, Bogdan; Rohland, Nadin; McLaren, Paul J et al. (2012) Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet 44:631-5
Hulgan, Todd; Robbins, Gregory K; Kalams, Spyros A et al. (2012) T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS One 7:e43803
Ribaudo, Heather J; Benson, Constance A; Zheng, Yu et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929-40
Grady, Benjamin J; Samuels, David C; Robbins, Gregory K et al. (2011) Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr 58:363-70
Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64
Cohn, Susan E; Jiang, Hongyu; McCutchan, J Allen et al. (2011) Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care 23:775-85
International HIV Controllers Study (see original citation for additional authors) (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-7

Showing the most recent 10 out of 13 publications